Maravai Lifesciences price target lowered to $5 from $10 at Stifel

3 weeks ago 8

Unlock banal picks and a broker-level newsfeed that powers Wall Street.

TipRanks

Sat, Mar 22, 2025, 7:30 AM 1 min read

In This Article:

Stifel lowered the firm’s price target connected Maravai Lifesciences (MRVI) to $5 from $10 and keeps a Buy standing connected the shares. The steadfast notes Q4 revenues came up $1M airy of the Street, portion EBITDA fell abbreviated by $7M. As for the guide, management’s outlook is good beneath Street, but excludes each precocious measurement CleanCap orders. Stifel believes the institution is astatine constituent wherever the modulation from COVID to non-COVID demand, the China uncertainty, and the opaqueness of cardinal exemplary country marque for a debased visibility situation. Maravai looks washed retired astatine $2-$3, but remains a low-confidence Buy until greater clarity is gained and amended maturation materializes, the steadfast adds.

Easily place stocks' risks and opportunities.
Discover stocks' marketplace presumption with elaborate rival analyses.

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See today’s best-performing stocks connected TipRanks >>

Read More connected MRVI:

Questions oregon Comments astir the article? Write to [email protected]

Maravai Lifesciences Projects 2025 Revenue and Expenses
Buy Rating for Maravai Lifesciences Holdings: Strategic Financial Decisions and Growth Potential Amidst Challenges
Maravai Lifesciences reports Q4 adjusted EPS (6c), statement (4c)
Maravai LifeSciences options connote 16.5% determination successful stock terms post-earnings
May 05, 2025 Deadline: Contact Levi & Korsinsky LLP to Join Class Action Suit Against MRVI

Read Entire Article